Shares of Genprex Inc (NASDAQ:GNPX) were up 2.3% during mid-day trading on Friday . The company traded as high as $2.26 and last traded at $2.20. Approximately 1,416 shares were traded during trading, a decline of 96% from the average daily volume of 36,661 shares. The stock had previously closed at $2.15.

A number of analysts have recently weighed in on the stock. Maxim Group reissued a “buy” rating and set a $3.00 price target on shares of Genprex in a research report on Tuesday, November 20th. ValuEngine downgraded shares of Genprex from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd.

An institutional investor recently bought a new position in Genprex stock. Intl Fcstone Inc. purchased a new position in shares of Genprex Inc (NASDAQ:GNPX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 35,150 shares of the company’s stock, valued at approximately $39,000. Intl Fcstone Inc. owned approximately 0.23% of Genprex at the end of the most recent quarter. Hedge funds and other institutional investors own 7.23% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at

Genprex Company Profile (NASDAQ:GNPX)

Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.

Featured Story: Cryptocurrencies

Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with's FREE daily email newsletter.